## ADUS: Addus HomeCare Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.11 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($106.60)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Addus HomeCare Corporation (NASDAQ:ADUS) Given Consensus Rating of "Moderate Buy" by Analysts**
- Source: MarketBeat | 20251217T090834 | Somewhat-Bullish | Relevance: 100%
- Analysts have given Addus HomeCare Corporation (NASDAQ:ADUS) a consensus "Moderate Buy" rating, with an average 12-month target price of $137.11. This follows recent strong Q3 earnings where the company exceeded revenue and EPS estimates. Despite some insider selling, institutional investors have increased their stakes, reflecting confidence in the home care provider.

**2. Insider Selling: Addus HomeCare (NASDAQ:ADUS) Director Sells 150 Shares of Stock**
- Source: MarketBeat | 20251217T070834 | Somewhat-Bearish | Relevance: 100%
- Addus HomeCare (NASDAQ:ADUS) Director Esteban Lopez sold 150 shares of the company's stock on December 15th at an average price of $115.18, totaling $17,277. This sale reduced his stake by 3.9% to 3,700 shares. The company's stock currently trades at $113.49 and analysts maintain a "Moderate Buy" rating with an average target price of $137.11.

**3. Is Addus HomeCare Corporation (NASDAQ:ADUS) Trading At A 48% Discount?**
- Source: 富途牛牛 | 20251215T170834 | Bullish | Relevance: 97%
- Addus HomeCare Corporation (NASDAQ:ADUS) is estimated to be undervalued by 48% according to a Discounted Cash Flow (DCF) model, with a fair value of US$219 compared to its current share price of US$115. This valuation implies a significant discount to its intrinsic value, which is also 55% higher than the analyst price target of US$142. The analysis relies on a 2-stage growth model and highlights the company's financial health, management, and alternatives.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($0.02M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 54.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Blackrock Inc.: 14.8% (-1.1%)
- Vanguard Group Inc: 7.0% (+2.9%)
- Capital Research Glo: 6.5% (+9.0%)
- Wasatch Advisors LP: 5.1% (+0.8%)
- Silvercrest Asset Ma: 4.6% (+14.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_20 improving +2.0% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.11 suggests fair value with growth premium. Balance sheet: low leverage (D/E 0.36). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.1B |
| Beta | 0.94 |
| 52W Range | $88.96 - $136.72 |
| Short Interest | 4.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.11 |
| Forward P/E | 16.5 |
| Current P/E | 18.3 |
| YoY Growth | 11.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -2.0% to 0.0% (+2.0% in 5 days), confirming momentum buildup. Below STRENGTH zone by 4.0pp (needs >4.0% for momentum thesis). MRS_5 at 0.9% confirms short-term momentum alignment. Long-term uptrend intact (above SMA200 at 1.03x) but short-term weakness (below SMA20). RSI neutral at 46. OFD pattern: -DUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.02% (CS: 30) | Neutral |
| RSI_14 | 45.5 | Neutral |
| MACD Histogram | -0.22 | Bearish |
| vs SMA20 | 0.981x | Below |
| vs SMA50 | 0.976x | Below |
| vs SMA200 | 1.026x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $112.98
- **Stop Loss:** $106.60 (5.6% risk)
- **Target:** $125.74 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 169
- **Position Value:** $19,093.62
- **Portfolio %:** 19.09%
- **Risk Dollars:** $1,080.00
- **Risk Per Trade:** 1.08%
- **Modifiers:** L1 90% | L2 120% | Combined 1.08x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_OFF (HIGH) | 0.90x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_OFF regime with deteriorating conditions. VIX rising to 17.6 (+11.7% over 5 days) signals increasing anxiety, while narrow breadth at 52.6% indicates selective participation. AI infrastructure cost concerns are pressuring tech leadership, creating sector rotation challenges in a late-cycle environment.*

### Earnings

**Next:** 2026-02-23 (Est: $1.72)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.53 | $1.56 | +1.7% |
| 2025Q2 | $1.46 | $1.49 | +1.8% |
| 2025Q1 | $1.33 | $1.42 | +6.5% |
| 2024Q4 | $1.36 | $1.38 | +1.6% |

---
*RULE-based L3 | 2026-01-07 01:41 | MRS_20*